Transcriptomic integration reveals immune heterogeneity in vascular dementia and identifies ELF2 as a candidate therapeutic target.
Overview
- Department of Neurology, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Department of Ultrasound, Jiading Branch of Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Abstract
Vascular dementia (VaD) is the second most prevalent form of dementia after Alzheimer’s disease and is primarily driven by chronic cerebral hypoperfusion and neurovascular dysfunction. Growing evidence indicates that immune dysregulation and neuroglial–vascular injury play critical roles in disease progression; however, the molecular regulators underlying these processes remain insufficiently characterized. This study aimed to delineate immune heterogeneity and neuroglial–vascular alterations in VaD and to identify key regulatory targets involved in disease pathogenesis. Bulk RNA sequencing data (GSE122063) and single-cell transcriptomic data (GSE282111) were retrieved from the Gene Expression Omnibus database and integratively analyzed to characterize immune infiltration patterns and cellular dysregulation. Immune profiling was performed using CIBERSORT and single-sample gene set enrichment analysis. Disease-associated cell subsets and hub genes were identified using Seurat, Scissor, and high-dimensional weighted gene co-expression network analysis (hdWGCNA). Pseudotime trajectory analysis and molecular docking were subsequently applied to investigate gene expression dynamics and potential therapeutic relevance. Bulk transcriptomic analysis revealed a pronounced pro-inflammatory shift in VaD brain tissue, characterized by increased infiltration of M1 macrophages, neutrophils, and activated dendritic cells, alongside reduced levels of M2 macrophages, resting CD4+ memory T cells, and regulatory T cells. Single-cell analysis demonstrated marked loss of oligodendrocytes, astrocytes, and endothelial cells in VaD. Scissor integration showed positive associations between VaD and oligodendrocytes, astrocytes, and endothelial cells, whereas microglia and oligodendrocyte progenitor cells were negatively associated. hdWGCNA identified 3 co-expression modules; intersection of the blue module with bulk differentially expressed genes highlighted DOCK3, ELF2, and Sin3A associated protein 25, with ELF2 uniquely co-expressed across relevant cell types. Pseudotime analysis indicated sustained downregulation of ELF2 during VaD-related cellular differentiation. Molecular docking analysis suggested strong binding affinities between ELF2 and nicergoline (−7.23 kcal/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE282111, at NCBI GEO; found in the text, “2.1. Data acquisition and preprocessing”
Other data links
- ncbi.nlm.nih.gov/
geo , NCBI; found in the text, “2.1. Data acquisition and preprocessing”
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 5 keywords, 8 MeSH terms, 30 references.
Cite
This paper
Liang, L., Shen, C., Huang, S., Hu, M., & Zhu, J. (2026). Transcriptomic integration reveals immune heterogeneity in vascular dementia and identifies ELF2 as a candidate therapeutic target. Medicine, 105(37), e50324. https://
BibTeX
@article{liang2026transc
author = {Liang, Li and Shen, Cuiqin and Huang, Shiren and Hu, Minglu and Zhu, Jian},
title = {{Transcriptomic integration reveals immune heterogeneity in vascular dementia and identifies ELF2 as a candidate therapeutic target}},
journal = {Medicine},
year = {2026},
month = sep,
volume = {105},
number = {37},
pages = {e50324},
publisher = {Wolters Kluwer Health},
issn = {0304-5412},
doi = {10.1097/
url = {https://
pmid = {42736768},
pmcid = {PMC13574462}
}
RIS
TY - JOUR
AU - Liang, Li
AU - Shen, Cuiqin
AU - Huang, Shiren
AU - Hu, Minglu
AU - Zhu, Jian
TI - Transcriptomic integration reveals immune heterogeneity in vascular dementia and identifies ELF2 as a candidate therapeutic target
T2 - Medicine
J2 - Medicine (Baltimore)
PY - 2026
DA - 2026/
VL - 105
IS - 37
SP - e50324
SN - 0304-5412
PB - Wolters Kluwer Health
DO - 10.1097/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1097/
"type": "article-journal",
"title": "Transcriptomic integration reveals immune heterogeneity in vascular dementia and identifies ELF2 as a candidate therapeutic target",
"container-title": "Medicine",
"author": [
{
"family": "Liang",
"given": "Li"
},
{
"family": "Shen",
"given": "Cuiqin"
},
{
"family": "Huang",
"given": "Shiren"
},
{
"family": "Hu",
"given": "Minglu"
},
{
"family": "Zhu",
"given": "Jian"
}
],
"container-title-short":
"volume": "105",
"issue": "37",
"page": "e50324",
"DOI": "10.1097/
"PMID": "42736768",
"PMCID": "PMC13574462",
"ISSN": "0304-5412",
"publisher": "Wolters Kluwer Health",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
9,
1
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3389/fnagi.2022.949074
- Accelerated aging-related transcriptome alterations in neurovascular unit cells in the brain of Alzheimer's disease.Journal: Frontiers in aging neuroscienceIn common: Alzheimer's / dementia, genetics / omics, cellular / molecular, 4 references
- [2] doi:10.1186/s12974-023-02908-5
- Cortistatin deficiency reveals a dysfunctional brain endothelium with impaired gene pathways, exacerbated immune activation, and disrupted barrier integrity.Journal: Journal of neuroinflammationIn common: genetics / omics, cellular / molecular, 3 references
- [3] doi:10.14336/ad.2021.1029
- Blocking C3d<sup>+</
sup>/ GFAP<sup>+</ sup> A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke. Journal: Aging and diseaseIn common: stroke, cellular / molecular, 3 references - [4] doi:10.1038/s42003-022-03784-0
- Long-term microglial phase-specific dynamics during single vessel occlusion and recanalization.Journal: Communications biologyIn common: stroke, cellular / molecular, 3 references
- [5] doi:10.1186/s12987-022-00312-4
- The blood-brain barrier and the neurovascular unit in subarachnoid hemorrhage: molecular events and potential treatments.Journal: Fluids and barriers of the CNSIn common: stroke, cellular / molecular, 3 references
- [6] doi:10.1111/cns.14742
- Inhibition of ADORA3 promotes microglial phagocytosis and alleviates chronic ischemic white matter injury.Journal: CNS neuroscience & therapeuticsIn common: stroke, Alzheimer's / dementia, cellular / molecular, 2 references
- [7] doi:10.1186/s12974-022-02579-8
- COVID-19 and cognitive impairment: neuroinvasive and blood‒brain barrier dysfunction.Journal: Journal of neuroinflammationIn common: Alzheimer's / dementia, 3 references
- [8] doi:10.3389/fgene.2025.1646991
- Comprehensive analysis and validation of angiogenesis in vascular dementia from the perspective of diagnosis, prevention, and treatment.Journal: Frontiers in geneticsIn common: stroke, Alzheimer's / dementia, genetics / omics, 2 references
- [9] doi:10.1371/journal.pbio.3002559 [code]
- Neuronal cell cycle reentry events in the aging brain are more prevalent in neurodegeneration and lead to cellular senescence.Journal: PLoS biologyIn common: Alzheimer's / dementia, genetics / omics, cellular / molecular, 3 references
- [10] doi:10.3389/fnmol.2022.751044
- Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses.Journal: Frontiers in molecular neuroscienceIn common: stroke, Alzheimer's / dementia, cellular / molecular, 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
